The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alessa Therapeutics for its lead product ...

Enolen is currently being studied in a Phase 1 trial evaluating its safety, tolerability and preliminary efficacy for localized sustained delivery of enzalutamide into the prostate. Alessa expects to ...

The rate of active surveillance as initial treatment increased from 2.0% in 2010 to 8.6% in 2020. The use of active surveillance in patients with intermediate-risk prostate cancer has increased in ...

Findings represent first validation of any gene expression biomarker for intermediate-risk patients using data from a randomized phase 3 clinical trial Prostate cancer deemed “intermediate risk” by ...

Autonomic nerve invasion may be simple method of identifying which patients with intermediate-risk T3a prostate cancer who have negative surgical margins after radical prostatectomy are at increased ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk prostate cancer treated with external-beam radiation therapy (EBRT), ...

Please provide your email address to receive an email when new articles are posted on . Men with low- or intermediate-risk prostate cancer achieved similar quality-of-life outcomes whether they ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

New Corewell Health™ research suggests an MRI scan can help predict whether patients with intermediate-risk prostate cancer (cancer confined to the entire prostate) may have more aggressive cancer in ...

It’s the second most common type of cancer among men and affects 1 in every 8 men in the United States. September is Prostate Cancer Awareness Month, and the American Cancer Society says this type of ...

A former prostate cancer patient who got the all-clear said taking part in a trial that cut his radiotherapy treatments ...

Prostate cancer diagnoses decreased by 28% in the first year following the US Preventive Services Task Force (USPSTF) recommendation against regular prostate specific antigen (PSA) screening, ...